Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, First-in-Human, Multicenter, Open-Label Study of ABSK131 to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy in Patients With MTAP-Deficient Advanced/Metastatic Solid Tumors

NCT07288957 is registered in ClinicalTrials.gov with Abbisko Therapeutics Co, Ltd as lead sponsor.

NCT NCT07288957
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07288957 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, First-in-Human, Multicenter, Open-Label Study of ABSK131 to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy in Patients With MTAP-Deficient Advanced/Metastatic Solid Tumors
Lead sponsor
Abbisko Therapeutics Co, Ltd
Phase
Phase 1
Overall status
Recruiting
Start date
July 22, 2025
Completion date
July 30, 2029
Enrollment
266 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumors (phase 1)